COPPER-ATOM IDENTIFICATION IN THE DIFFERENT ACTIVE AND INACTIVE FORMS OF RECOMBINANT FACTOR-VIII-DELTA-II AND PLASMA-DERIVED FACTOR-VIII

被引：0
|
作者：
BIHOREAU, N
RAMON, C
PIN, S
FONTAINEAUPART, MP
机构：
[1] LAB FRANCAIS FRACTIONNEMENT & BIOTECHNOL,LES ULIS,FRANCE
[2] UNIV PARIS 11,PHOTOPHYS MOLEC LAB,F-91405 ORSAY,FRANCE
[3] UNIV DENIS DIDEROT,BIOL PHYSICOCHIM LAB,PARIS,FRANCE
来源：
THROMBOSIS AND HAEMOSTASIS | 1995年 / 73卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [31] HEPATITIS-A VIRAL SAFETY OF PLASMA-DERIVED FACTOR-VIII CONCENTRATE KOATE(R)-HP
    MITRA, G
    DOBKIN, M
    DUMAS, M
    NG, P
    ROLDAN, G
    GALLOWAY, C
    VOX SANGUINIS, 1994, 67 : 80 - 82
  • [32] Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays
    Knappe, Sabine
    Till, Susanne
    Scheiflinger, Friedrich
    Dockal, Michael
    HAEMOPHILIA, 2014, 20 : 28 - 28
  • [33] Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia
    van der Bom, Johanna G.
    Gouw, Samantha C.
    van den Berg, H. Marijke
    BLOOD, 2007, 110 (03) : 1074 - 1075
  • [34] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
    Neufeld, Ellis J.
    Sidonio, Robert F., Jr.
    O'Day, Ken
    Runken, M. Chris
    Meyer, Kellie
    Spears, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
  • [35] Trial Results Reveal Greater Risk of Inhibitor Formation in Patients With Hemophilia A Receiving Recombinant Factor VIII Than in Patients Receiving Plasma-Derived Factor VIII
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 20 - 21
  • [36] Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
    Qadura, Mohammad
    Waters, Braden
    Burnett, Erin
    Chegeni, Rouzbeh
    Bradshaw, Scott
    Hough, Christine
    Othman, Maha
    Lillicrap, David
    BLOOD, 2009, 114 (04) : 871 - 880
  • [37] Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A
    Steele, M.
    Chan, A.
    Nagel, K.
    HAEMOPHILIA, 2012, 18 : 35 - 35
  • [38] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [39] Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
    Peyvandi, F.
    Cannavo, A.
    Garagiola, I.
    Palla, R.
    Mannucci, P. M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (01) : 39 - 43
  • [40] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
12345